Role of spiramycin in prevention of fetal toxoplasmosis

Basit Öğe Kaydı
dc.authorid0000-0001-8554-7651
dc.contributor.authorAvcı, Muhittin Eftal
dc.contributor.authorArslan, Ferhat
dc.contributor.authorÇiftci, Şinasi
dc.contributor.authorEkiz, Ali
dc.contributor.authorTüten, Abdullah
dc.contributor.authorYıldırım, Gökhan
dc.contributor.authorMadazlı, Rıza
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:58:32Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:58:32Z
dc.date.issued2016
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı
dc.descriptionWOS: 000374773800006
dc.descriptionPubMed ID: 26365472
dc.description.abstractObjective: The aim of this study is to evaluate the efficacy of spiramycin in prevention of mother-to-child transmission of Toxoplasma gondii infection. Methods: Patients within first trimester of their pregnancy with Toxoplasma IgM positivity (>0.65 index, ELISA, VIDAS) and IgG positivity (>8 IU/ml), who had low IgG avidity (<0.50 index, ELISA, Architet) were considered as having acute toxoplasmosis. These patients who had amniocentesis at the 19th-21st week of pregnancy were examined for the detection of Toxoplasma DNA. Detailed ultrasonographic examinations performed between the 20th and 24th gestational weeks and the mothers and babies were followed for at least one year. Results: Out of 61 patients, 55 (90.2%) had received Spy prophylaxis while 6 (9.8%) cases refused Spy prophylaxis. Toxoplasma PCR test was found to be positive in amniotic fluid of 4 (6.6%) patients obtained by amniocentesis at the 19th-21st week of pregnancy. All four of these patients had refused Spy prophylaxis had positive Toxoplasma PCR in amniotic fluid (p<0.01). Conclusion: Our results seem to encourage the use of spiramycin in women with toxoplasmosis during pregnancy.
dc.identifier.citationAvcı, M. E., Arslan, F., Çiftci, Ş., Ekiz, A., Tüten, A., Yıldırım, G. ... Madazlı, R. (2016). Role of spiramycin in prevention of fetal toxoplasmosis. Journal Of Maternal-Fetal & Neonatal Medicine, 29(13), 2073-2076. https://dx.doi.org/10.3109/14767058.2015.1074998
dc.identifier.doi10.3109/14767058.2015.1074998
dc.identifier.endpage2076
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.issue13
dc.identifier.scopusqualityQ2
dc.identifier.startpage2073
dc.identifier.urihttps://dx.doi.org/10.3109/14767058.2015.1074998
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3188
dc.identifier.volume29
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAmniocentesis
dc.subjectPCR
dc.subjectProphylaxis
dc.subjectSpiramycin
dc.subjectToxoplasma Gondii
dc.titleRole of spiramycin in prevention of fetal toxoplasmosis
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Arslan-Ferhat 2016.pdf
Boyut:
660.52 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu